Austar Lifesciences Limited

OTCPK:AULS.F Stock Report

Market Cap: US$44.0m

Austar Lifesciences Past Earnings Performance

Past criteria checks 0/6

Austar Lifesciences has been growing earnings at an average annual rate of 21.9%, while the Life Sciences industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 20.4% per year.

Key information

21.9%

Earnings growth rate

21.9%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate20.4%
Return on equity-4.5%
Net Margin-1.8%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Austar Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:AULS.F Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,764-3333355
30 Jun 232,089234364
31 Mar 232,1594532767
31 Dec 222,15710430370
30 Sep 222,2469630771
30 Jun 222,26410530472
31 Mar 222,13919130469
31 Dec 212,01527730466
30 Sep 211,82425830459
30 Jun 211,63323830452
31 Mar 211,46513628150
31 Dec 201,2963325948
30 Sep 201,1932525347
30 Jun 201,0891724645
31 Mar 201,0691224844
31 Dec 191,049825143
30 Sep 191,007823439
30 Jun 19966821636
31 Mar 19891420033
31 Dec 18817018330
30 Sep 18724-1618229
30 Jun 18631-3318228
31 Mar 18589-4317727
31 Dec 17547-5417126
30 Sep 17587-4316027
30 Jun 17628-3214928
31 Mar 17650-2515030
31 Dec 16673-1915132
30 Sep 16648-1714632
30 Jun 16624-1614131
31 Mar 16626-513429
31 Dec 15628612727
30 Sep 156402412226
30 Jun 156524311826
31 Mar 156665412025
31 Dec 146806512224
30 Sep 146765812824
30 Jun 146725113324
31 Mar 146895212624
31 Dec 137055412024

Quality Earnings: AULS.F is currently unprofitable.

Growing Profit Margin: AULS.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AULS.F is unprofitable, but has reduced losses over the past 5 years at a rate of 21.9% per year.

Accelerating Growth: Unable to compare AULS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AULS.F is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-10.8%).


Return on Equity

High ROE: AULS.F has a negative Return on Equity (-4.49%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/08/10 18:05
End of Day Share Price 2024/05/13 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Austar Lifesciences Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Milo LiuBOCOM International Securities Limited
Forrest ChanCCB International Securities Limited
Tsz Man ChanKGI Securities Co. Ltd.